BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Martek Biosciences Corporation (MATK) Added To The S&P MidCap 400 Index


10/19/2005 5:12:51 PM

COLUMBIA, Md., Feb. 25 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation announced today that the Company will be added to Standard & Poor's MidCap 400 after the close of trading on Tuesday, March 1st. The S&P MidCap 400 is the most widely used index for mid-sized companies, according to Standard & Poor's.

"Martek is pleased to be added to the S&P MidCap 400 index. Inclusion in this popular index should broaden the company's exposure to investors," said Henry Linsert Jr., CEO of Martek.

The S&P MidCap 400 covers approximately 7% of the U.S. equities market, and is part of a series of S&P U.S. indices that can be used as building blocks for portfolio construction. Standard & Poor's reports that today mid- caps are recognized as an independent asset class, with risk/reward profiles that differ considerably from both large-caps and small-caps.

Martek Biosciences Corporation develops, manufactures and sells products from microalgae. The Company's products include: (1) specialty, nutritional oils for infant formula that aid in the development of the eyes and central nervous system in newborns; (2) nutritional supplements and food ingredients that may play a beneficial role in promoting mental and cardiovascular health throughout life; and (3) new, powerful fluorescent markers for diagnostics, rapid miniaturized screening, and gene and protein detection.

This press release contains forward-looking statements regarding the commercialization of Martek's products. Such statements involve risks and uncertainties that could cause future actual results to differ due to a variety of risk factors, including without limitation those factors set forth in Martek's filings with the Securities and Exchange Commission.

Contact: Beth Parker, Manager, Public Relations (443) 542-2551.

Martek Biosciences Corporation

CONTACT: Beth Parker, Manager, Public Relations of Martek BiosciencesCorporation, +1-443-542-2551



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES